抗乙肝病毒新型藥物研發進展

上次，小編簡介了夏宇塵等學者關於肝炎病毒致肝癌機制的論文。這次，隨小編對他們在Gastroenterology雜誌（影響因子20.77）上新發表的綜述《直接作用的抗乙肝病毒和宿主靶向藥物的研發進展》先睹為快吧！

乙肝病毒感染影響了世界上300，000，000人。儘管抗病毒治療已改善了長期效果，病人常需要終身治療，且沒有乙肝病毒感染治癒的先例。新技術可以幫我們了解更多乙肝病毒的發病機制，研發治療藥物以減輕其負擔。本文綜述了直接作用的抗病毒藥物和宿主靶向藥物研發的最新成果，其中一些已經進入了臨床實驗，還論述了高通量篩查以鑒別抑制乙肝病毒的化合物和現有藥物再利用的策略。

感興趣的讀者可以下載閱讀！

下載地址：https://doi.org/10.1053/j.gastro.2018.07.057

Abstract

Hepatitis B virus (HBV) infection affects about 300 million people worldwide. Although antiviral therapies have improved the long-term outcomes, patients often require life-long treatment and there is no cure for HBV infection. New technologies can help us learn more about the pathogenesis of HBV infection and develop therapeutic agents to reduce its burden. We review recent advances in development of directing-acting antiviral and host-targeting agents, some of which have entered clinical trials. We also discuss strategies for unbiased high-throughput screens to identify compounds that inhibit HBV and for repurposing existing drugs.

本期編輯：烏龜

喜歡這篇文章嗎？立刻分享出去讓更多人知道吧！